InnovaTV207 SGNTV 001 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. SGNTV001
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Seagen, Inc
Start Date
March 12, 2024
End Date
April 15, 2029
Administered By
Duke Cancer Institute
Awarded By
Seagen, Inc
Start Date
March 12, 2024
End Date
April 15, 2029